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Abstract
Background: Carrageenan is a sulfated polysaccharide that exists in red seaweeds recently shown to have anticancer
properties. Previous findings show various effects of carrageenan suppressing tumor cell growth. One of the hallmarks
of cancer is uncontrolled proliferation, a consequence of loss of normal cell-cycle control, that underlies tumor growth.
Recently there is an increasing interest in potential anticancer agents that affect cell cycle in cancer cells. Thus, in this
study we investigated the effects of carrageenan on the tumor cell cycle.
Methods: Using human cervical carcinoma cells (HeLa) cells as and human umbilical vein endothelial cells (HUVEC),
the cytotoxic effects of kappa carrageenan (k-CO) and lambda carrageenan (λ-CO) at the concentrations of 250–
2500 μg/mL were observed. Cell viability was determined using the MTT assay while cell death rates were determined
using staining with calcein-AM/propidium iodide. Cell-cycle profile and progression were demonstrated with HeLa cells
expressing FUCCI (fluorescence ubiquitination-based cell-cycle indicator) probes (HeLa-FUCCI).
Results: Carrageenan had no significant effect on HUVEC (normal cells). In contrast both forms of carrageenan were
cytotoxic towards HeLa cells (cancer cells). Furthermore, according to cell-cycle analysis with FUCCI cells, the cell cycle
of HeLa cells was delayed in specific phases due to different carrageenan treatments.
Conclusion: Considering these results, it could be suggested that carrageenan affects the cell-cycle of HeLa cells not
only by arresting the cell cycle in specific phases but also by delaying the time needed for the cell to progress through
the cell cycle. Additionally, different types of carrageenans have different effects on cell cycle progression. This effect of
carrageenan towards cancer cells could possibly be developed into a tumor cell-specific anticancer agent.
Keywords: Carrageenan, Algae, Cancer, Cell cycle, Human cervical carcinoma cells, Human umbilical vein endothelial
cells, Fluorescence ubiquitination-based cell-cycle indicator
Background
Cancer is the leading cause of death worldwide, account-
ing for more 8.2 million deaths in recent years [1]. Many
polysaccharides have been isolated from mushrooms,
fungi, yeast, algae, lichens and plants in the search for po-
tential anticancer drugs. The biological activities of these
polysaccharides have attracted considerable attention in
the biotechnology and medical fields [2]. In the search
for novel compounds with antitumor properties, marine
bioresources have become particular interest given their
unique bioactivities [3]. Marine algal cell walls were re-
ported to contain sulfated polysaccharides, which are not
found in land plants and may have specific functions in
ionic regulation [4]. Later studies revealed sulfated
polysaccharides from marine algae have many biological
and physiological activities including anticoagulant [5],
antithrombotic [6], anti-inflammatory [7], antiviral [8],
and activities [9].
A sulfated polysaccharide from algae that has been
recently studied because of its interesting bioactivities
is carrageenan. Carrageenan is a highly sulfated polysac-
charide found in marine red algae of the family Rhodo-
phyceae [10]. Carrageenan is used as a stabilizer, gelling
agent, thickener, binder and additive in various food and
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pharmaceutical industries. Carrageenans are composed
of linear chains of D-galactopyranosyl units linked via
alternated (1→ 3)-β-D-and (1→ 4)-α-D-glucoside [11], in
which sugar units have one or two sulfate groups. From
the commercial point of view, the most important cara-
geenans can be categorized into kappa (k-), iota (i-), and
lambda (λ-) carrageenans, which differ in the number and
position of the sulfate groups. Analysis of their structures
can be performed by acidic hydrolysis, for which methods
have been developed based on reductive hydrolysis
[12–14]. Additionally recent studiesshowthatcarrageenan,
exhibits many biological and physiological activities be-
sides its antitumor potential [15], including anticoagulant
[16, 17], antithrombotic [18, 19], and anti-inflammatory
properties [20, 21]. However, in the present study we
would like to demonstrate carrageenan mechanism in
affecting tumor cell cycle. Previous findings found that
carrageenan has the potential to arrest the cell cycle in
certain stages such as G2 [22] or S phase [23]. Many con-
ventional anticancer treatments kill cells regardless of
whether these cells are normal or cancerous. Based on the
discovery that cell cycle characteristics of cancer cells are
different compared to normal cells, potential antitumor
agents that are able to affect the cell cycle could be a good
target for antitumor drug research. Thus, we suggest
it would be important to study how carrageenan affects
the cell cycle of human cancer cells. In the present study
we demonstrate for the first time cell cycle progression
of effected human cancer cells by kappa carrageenan
(k-CO) and lambda carrageenan (λ-CO) with fluores-
cence ubiquitination-based cell cycle indicator (FUCCI)
that was developed by Sakaue-Sawano et al. [24]. With
FUCCI, we are able to observe cell-cycle progression in
real time by measuring the expression of an orange-red
fluorescent protein by G0/G1 cells and a yellow-green
fluorescent protein by S/G2/M cells.
Method
Cell culture and treatment
The cell line that was used in this experiment for cyto-
toxicity analysis was Human Carcinoma Cervical Cell
lines (HeLa) for human tumor cell models and Human
Umbilical Vein Endothelial Cells (HUVEC) for human
normal cell models. Cell cycle progression was observed
by HeLa cells (HeLa-FUCCI) expressing the FUCCI
(fluorescent ubiquitiniation-based cell cycle indicator)
probes provided by the RIKEN BioResource Centre
(RIKEN BRC). HeLa cells were maintained in Dulbecco’s
Modified Eagle’s Medium from Sigma-Aldrich supple-
mented with 10 % fetal bovine serum (FBS), at 37 °C in
5 % CO2 humidified atmosphere. HUVEC were cultured in
Molecular, Cellular, and Developmental Biology (MCDB)
131 medium supplemented with 10 ng/mL epidermal
growth factor, 10 μg/mL heparin and 10 % FBS.
Carrageenan treatment
HeLa and HeLa-FUCCI cells were seeded at a density of
2x105 cells/well in 96 well plates containing Dulbecco’s
Modified Eagle’s Medium supplemented with 10 % FBS.
HUVEC were cultured in MCDB 131 medium supple-
mented with 10 ng/mL epidermal growth factor, 10 μg/
mL heparin and 10 % FBS. After overnight incubation,
k-CO and λ-CO (purchased from Sigma-Aldrich) were
added to each assay at concentrations of 250,500,1000,
or 2500 μg/mL were added to each assay and maintained
at 37 °C in a water saturated atmosphere containing 5 %
CO2. Cells were incubated in the presence of k-CO and
λ-CO for 72 h before cell count analysis.
Cell growth inhibtion assay
Cell growth conditions of HeLa and HUVEC as a re-
sult of exposure to k-COand λ-CO were determined
using the Methyl Thiazolyl Tetrazolium (MTT) assay
in 96 well plates after carrageenan treatment for 3 days.
Cell counting was performed Flexstation 3 Multi_mode
Microplate Reader at an absorbance of 450 nm. The
viability of the cells was calculated according to the
following equation:
Cell viability %ð Þ ¼ ð Abs460 sample – Abs460 blankð Þ=
Abs460 untreated – Abs460 blankð Þ
x 100 %Þ
Manual cell count were also conducted using a
hemocytometer and triplicate readings were recorded.
Inhibitory activity expressed as the 50 % inhibition con-
centration (IC50) is the concentration of carrageenan
that can inhibit cell growth by 50 % [25]. The IC50 values
were calculated using the following formula to deter-
mine the regression equation y = a + bx.
Quantification of live and dead cells
To quantify the ratio of live/dead cells, cells were stained
with the fluorescent probes calcein AM and propidium
iodide (PI). Because of the permeable ability of the cell
membrane, calcein AM was used to stain viable cells,
while PI was used to label dead cells HeLa and HUVEC
were plated onto 35 mm2 glass-bottom culture dishes and
cultured overnight to achieve cell adhesion. Then cells
were treated with different concentrations (250,500,1000,
or 2500 μg/mL) of K-CO and λ-CO. After 72 h treatment,
the cells were washed three times with a PBS, followed by
incubation with a PBS solution mixed with 2 μL calcein
AM at 37 °C for 15 min. Finally, cells were stained with
2 μL PI before visualization under. BZ-9000 fluorescence
microscope (Keyence, Osaka, Japan). The dead cell ratio
was calculated using Image J software [26].
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Cell cycle profile analysis
Cell cycle profiles of the cells following treatment with
k-CO and λ-CO were observed using HeLa-FUCCI cells
over72h. FUCCI was developed to visualize the dynam-
ics of cell cycle progression. HeLa-FUCCI cells express
two fusion proteins : monomeric Kusabira Orange 2
(mKO2) fused to amino acids 30–120 of Cdt1, and
monomeric Azami Green fused to amino acids 1–110 of
Geminin. This combination of fused proteins causes
cells to emit red fluorescence at the early G1 phase im-
mediately after mitosis, and emit green fluorescence in
S/G2/M phases. After 72 h treatment of carrageenan on
HeLa-FUCCI cells cultured in 35 mm2 glass bottom
dishes, scanning microscopy was performed with the Bz-
9000 fluorescent microscope (Keyence). Scanning and
image acquisition were controlled using Bz-II analyzer
software (Keyence). The tracing data were imported to
Image J for quantification of cells emitting fluorescence
of each cell cycle phase.
Time-lapse Imaging
For a more accurate observation of cell cycle progression
due to carrageenan treatment, we set up time-lapse
imaging observation with 10 min interval for 72 h. HeLa-
FUCCI cell cycle progress was captured using a BIOREVO
BZ-9000 fluorescence microscope (Keyence). During im-
aging, cells were cultured in 35 mm2 glass-bottom dishes,
held in an incubation chamber to maintain temperature
at 37 °C with humidified atmosphere containing 95 % air/
5 % CO2. Average time of cells from six independent ob-
servations to complete cell-cycle phases were calculated
for cell-cycle time estimation.
Results
Effects of k- and λ- carrageenan on cell growth of normal
human cells in vitro
The aim for the discovery of potential anticancer agents
is that there must be a difference in the killing rate be-
tween normal cells and tumor cells. Thus, we sought to
determine if carrageenan had cytotoxic effects towards
normal human cells, using HUVEC. According to MTT
assay readings, both carrageenans had no significant
cytotoxic effect towards HUVEC suggesting little effect
on the viability of l normal human cells viability (Fig. 1).
Effects of K- and λ- carrageenan on cell growth of human
cancer cells cells in vitro
Both types of carrageenan were seen to affect human
cancer cell growth significantly. Figure 2a displays MTT
Fig. 2 Cytotoxic assay of HeLa cells treated with K-CO and λ-CO. a. HeLa cells were treated with K-CO and λ-CO in 72 h. Cell viability was
determined by MTT assay. Results are means ± SD, n = 3 independent observations. b. To confirm the result of previous MTT-assay, total cell
number of carrageenan treated HeLa cells were determined with Haemocytometer cell counter. Exposure of k-CO and λ-CO was associated with
inhibited cell growth in exposed vs untreated cells and with exposure to higher carrageenan concentration. Results are means ± SD, n= 3
independent observations
Fig. 1 MTT-assay of HUVEC cells treated with K-CO and λ-CO.
HUVEC cells were treated with K-CO and λ-CO in 72 h. Cell viability
was determined by MTT assay. Results are means ± SD, n = 3
independent observations
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assay results illustrating decreased cell viability of HeLa
cells exposed with k-CO and λ-CO over a 72 h period.
Furthermore, cell growth rates were determined by
total cell count of the cells using a haemocytometer.
Both k-CO and λ-CO suppressed HeLa cell growth as
cell number decreased as carrageenan concentration in-
creased (Fig. 2b). Both k-CO and λ-CO demonstrated IC50
values of 550.8 ± μg/mL and 475 ± 12 μg/mL, respectively
(Table 1). From these results, it could be assumed that λ-
CO possesses stronger cytotoxicity properties compared
with k-CO.
Viability staining assay
Viability staining was necessary for further confirmation
of the current result. Viability staining is an essential tool
to obtain a clear picture of cell viability towards treatment
of potential drugs. The cytotoxic properties of k-CO and
λ-CO were investigated further using a double-labeling
procedure with the fluorescence markers calcein-AM and
PI, which simultaneously stain live and dead cells in green
and red, respectively. Intracellular esterases in live cells
can convert the virtually nonfluorescentcell-permeable
calcein-AM into the intensely fluorescent calcein. PI en-
ters cells with damaged membranes and enhances fluores-
cence by binding to DNA, thereby producing a bright red
fluorescence in dead cells [27]. HeLa cells were treated
with k- and λ- carrageenan at concentrations of 250–
2500 μg/mL for 72 h then loaded with calcein-AM and PI
before observation with fluorescence microscopy. The
population of live (calcein-positive) and dead (PI-positive)
cells can be easily differentiated.
As shown in Fig. 3a, there was no increase in cell death
ratio of HUVEC treated with carrageenan compared with
untreated cells. Viability staining images of HUVEC cells
with Calcein-AM/PI also resulted in no significant differ-
ence between cells treated with carrageenan and untreated
cells (Fig. 3b). Conversely, an increased cell death ratio
Fig. 3 Viability staining of HUVEC cells treated with k-CO and λ-CO. a. Dead cell ratio of HUVEC cells exposed with k-CO and λ-CO previously
stained by calcein-AM/PI, quantified using imageJ software. Results are means ± SD, n= 3 independent observations. b. Viability staining of
HUVEC cells treated with concentrations of k-CO and λ-CO 250 μg/ml to 2500 μg/ml showed that λ-CO induces anti-proliferative effects resulting
in lower cell density. PI staining (red) indicates dead cells and Calcein AM staining (green) indicates viable cells (scale bar, 100 μm)
Table 1 Inhibition carrageenan concentrations causing 50 %
cell death (IC50) of 72 htreatment
Treatment IC50 (μg/mL)
k-CO 550.8 ± 7.6
λ- CO 475 ± 12
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was observed in HeLa cells treated with both carrageenan
treatments (Fig. 4a). Treatment with k-CO resulted in a
higher percentage of cell death in a dose-dependent fash-
ion. At maximum concentrations dead cell percentage of
k-CO treated cells were higher compared with λ-CO. In
contrast, we assumed λ-CO possessed stronger toxic
properties towards HeLa cells. Thus, we estimated λ-CO
treatment with λ-CO would result in a higher percentage
of dead cells. However, this disparity was explained by im-
ages from fluorescence microscope showing live images of
carrageenan treated cells stained with calcein-AM/PI
(Fig. 4b). Observed cells treated with λ-CO were seen to
result have a lower cell confluence in a concentration
dependent manner. Considerable differences in the cell
densities of cells treated with both carrageenans were no-
ticed at maximum concentration. Cells treated with λ-CO
for 72 h struggled to reach cell confluence compared to
with k-CO, showing a strong inhibition towards HeLa cell
proliferation.
Cell-cycle effects
We observed the cell cycle profiles of HeLa cells ex-
pressing FUCCI (HeLa-FUCCI) treated with increasing
concentrations of k-CO and λ-CO for 72 h. Untreated
control HeLa-FUCCI cells exhibited a combination of
orange-red and yellow-green nuclei (Fig. 5a) with high
cell density. Increased concentration of both k-CO and
λ-CO were seen to result in decrease of HeLa-FUCCI
cellular density. Cell cycle profiles of k-CO treated cells
showed increased arrest in the G2/M phase as green
cells (G2/M phase expressing cells) (Fig. 5b). However
λ-CO treatment was seen to have no effect on the
cell-cycle of HeLa cells, as there were no significant
differences between cell ratios of untreated and treated
cells (Fig. 5c). Thus further investigation was needed
regard on cell-cycle arrest points in carrageenan treated
HeLa cells.
Live cell imaging of cell cycle progress
To obtain more clear information on the effects of car-
rageenan towards cell-cycle progress in HeLa cells, we
set up time-lapse imaging observation for HeLa-FUCCI
cells exposed to k-CO and λ-CO at 1000 μg/mL. Images
were taken every 10 min for 72 h and the length of time
for each cell phase was measured. Exact lengths of time
for each cell phase altered by carrageenan treatment
Fig. 4 Viability staining of HeLa cells treated with k-CO and λ-CO. a. Dead cell ratio of HeLa cells exposed with k-CO and λ-CO previously stained
by calcein-AM/PI, quantified using imageJ software. Results are means ± SD, n= 3 independent observations. b. Viability staining of HeLa cells
treated with concentrations of k-CO and λ-CO 250 μg/ml to 2500 μg/ml showed that λ-CO induces anti-proliferative effects resulting in lower cell
density. PI staining (red) indicates dead cells and Calcein AM staining (green) indicates viable cells (scale bar, 100 μm)
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would provide a more effective conclusion regarding cell
cycle profiles. As seen in Fig. 6, the lengths of time
needed for cells to complete a specific cell-cycle phase
were compared. Times displayed are averaged from six
independent observations. Untreated cells required ap-
proximately 26 ± 0.67 h (Table 2) to complete one cell
cycle continuously dividing more than two times. While
cells treated with k-CO and λ-CO required a longer time
to complete cell cycle. Cells treated with k-CO were seen
to require a longer time to complete the G2/M phase,
correlating with the previous result which showing a
higher ratio of cells in the G2/M phase. Lengths of time
of G2/M phase cells treated with k-COwere also seen to
show double the time compared with G1 phase time. Cells
treated with λ-CO needed a longer time to complete one
cycle, approximately 59 ± 4.6 h. This was the result of
elongated times for both G1 and G2/M phases, which re-
sulted in a delay in cell-cycle progress overall compared
Fig. 6 Time lapse imaging of Fucci cells treated with k-CO and λ-CO. Analyse of cell cycle periods via real time lapse imaging of Fucci cells at the
transition from G2 as starting phase under carrageenan treatment. Images were taken at a time interval of 10 minutes to observe time length of
each cell phase. Displayed times are means from 6 observed cells (scale bar, 50 μm)
Fig. 5 k-CO and λ-CO effects on cell cycle. a. Fluorescent images of FUCCI cells treated with k-CO and λ-CO in 72 h (scale bar, 100 μm). b.
Percentages of cells expressing specific cell phase based on fluorescence color in 72 h after κ-carrageenan treatment c. Percentages of cells
expressing specific cell phase based on fluorescence color in 72 h after λ-carrageenan treatment
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with k-CO treatment which was 50.2 ± 2.9 h. This result
explains the previous finding that λ-CO was seen to have
no effect on the ratio of cells in cell-cycle phases. Delayed
time in both phases (G1 and G2/M) which time lengths
were similar resulted in an equal ratio cell in both cell
cycle phases. Furthermore, compared with cells treated
with k-CO, most cells treated with λ-CO were unable to
undergo cell division. Cell cycle progress seems to con-
tinue as FUCCI cells change color, except the cells are un-
able to divide and would later die. However, cells treated
with k-CO were able to divide at least once before cell
death. Based on these results, we suggest that λ-CO po-
tentially possesses a stronger effect on suppressing tumor
cell proliferation and cell division compared with k-CO.
Discussion
Carrageenan is a polysaccharide that exists in the cell
walls of marine red algae and is widely used in studies
concerned with its antitumor and cytotoxic activities [10].
Previous findings show carrageenan as a potential antitu-
mor agent [28–30]. Considering one of the hallmarks of
cancer is uncontrolled proliferation, a consequence of the
loss of normal cell-cycle control, there has been a. increas-
ing interest in potential anticancer agents that affect the
cell-cycles of cancer cells [31]. Thus, in this study we in-
vestigated how carrageenan affects tumor cell cycle.
In this study we demonstrated cytotoxic effects of car-
rageenan towards cell cycle of human cancer cells in
HeLa expressing FUCCI probes [24]. Two types of carra-
geenan, kappa (k-CO) and lambda (λ-CO) carrageenan
were used because sulfate contents vary in each type of
carrageenan [32]. These sulfated moieties in saccharides
are believed to play an important role in manifestation
of beneficial bioactivity [33]. Thus cytotoxic properties
of λ-CO which has more sulfate groups might differ
from k-CO. Cytotoxic effects are generally considered as
effects of a compound resulting in cell damage or death
[34]. Our current results show dissimilar properties of
k-COand λ-CO in effecting cell proliferation, cell death ra-
tio, and cell cycle progression.
In vitro cytotoxicity tests are mainly performed to
screen potentially toxic compounds that affect basic mo-
lecular functions such as cell growth. For acute toxicity
measurement, 3 h of exposure is sufficient to reulst in
toxic effects in the cell [35]. In the case of measuring cell
proliferation, the time of exposure should be 72 h, be-
cause that amount of time is required to obtain about
three cell divisions [36]. The HeLa cell line chosen as
models for this investigation is an immortal cell line gen-
erally used in toxicity tests. The ability of this cell line to
proliferate rapidly makes it possible to conduct several ex-
periments aimed mainly at detection of biological activity
of test substances and also provide long-term culture [37].
The cytotoxic effects of compounds can be classified by
the IC50 values. IC50 values less than 100 μg/mL indicate a
potentially cytotoxic compound. IC50 values in the range
of 100–1000 μg/mL are considered to correspond with
moderate cytotoxic effects, and compounds with IC50
values greater than 1000 μg/mL are considered non-toxic
to the cells [38, 39]. In this study, k-CO and λ-CO both
were found to cause moderate toxic effects on HeLa
cells because IC50 values were in the range of 100–
1000 μg/mL (Table 2). However λ-CO potentially pos-
sesses stronger cytotoxic effect compared with k-CO
based on IC50 values. λ-CO was reported to have higher
sulfate content than k-CO which results in stronger anti-
oxidant activity. Furthermore, high antioxidant activity
may potentially result in anti-proliferative effects [40].
However, further studies are needed to confirm the correl-
ation between sulfate content and anti-proliferative prop-
erties. Live:dead cell assays were performed to examine
cell death through determination of intracellular esterase
activity and plasma membrane integrity. The data showed
k-CO resulted in a higher ratio of dead cells after staining
with calcein-AM and PI. However, images of HeLa cells
treated with λ-CO displayed lower cellular confluence
implying cellular proliferation is suppressed by the anti-
proliferative potential of λ-CO. The findings of the current
study are consistent with those of other studies that
showed cell death induced via cellular toxicity caused by
carrageenan treatment in human tumor cells [41]. To de-
termine the cytotoxic effects of carrageenan on human
normal cells, we used HUVEC. Both k-CO and λ-CO
showed no significant cytotoxic effects towards HUVEC
viability. We expected cancer cells to be generally resistant
to apoptosis compared with normal human cells. How-
ever, as seen in responses to potential anticancer agents in
cell cultures, most cancer cell lines are more sensitive to
apoptosis compared with normal cell lines [42, 43].
Cell cycle arrest and cell death are two important
mechanisms involved in anti-cancer drug development.
Uncontrolled cellular proliferation is a general character-
istic of all cancer cells, and the blockade of the cell cycle
is regarded as an effective strategy for eliminating
cancer cells. Many chemotherapeutic agents have shown
anti-proliferative effects via arresting cell division at
certain checkpoints in the cell cycle. The concept of
cell cycle-mediated cell death has gained increasing
Table 2 Time required for cells to undergo phases of cell cycle
in treatment of k-CO and λ-CO (1000 μg/mL). Data presented
are means of ± SD, n = 6 independent observations
Treatment Time length (h)
G0/G1 G1 G1/S S/G2/M 1 Cycle
Untreated cells 1.5 ± 0.7 9.3 ± 1.8 1.7 ± 0.8 14.1 ± 1.9 26.6 ± 0.6
K-carrageenan 1.0 ± 1.1 16.8 ± 4.0 2.2 ± 1.2 30.1 ± 7.3 50.2 ± 2.9
λ-carrageenan 1.3 ± 0.4 26.5 ± 4.9 2.5 ± 0.2 32.5 ± 5.1 59 ± 4.6
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attention, as targeting this pathway may provide an
opportunity to overcome drug resistance, decrease
mutagenesis and reduce toxicity.
In the present study we demonstrated a different method
in determining the cell-cycle profile via a modified fluores-
cent indicator of cell-cycle progression (Fig. 7) expressed in
HeLa cells. Observation using fluorescence microscopy re-
vealed clear distinct red, green and a small fraction of
doubly fluorescent cells [44]. Our results based on cell
cycle ratio showed a diverse distribution of G1 and G2/M
phase cells in untreated cells in 72 h. Cells treated with K-
CO showed cell-cycle arrest at the G2/M phase. The in-
crease in the ratio of cells in the G2/M phase was linier in
relation to the increase in concentrations of K-CO. Inter-
estingly, λ-CO did not show any correlation with cell-cycle
arrest as a result of increased concentrations based on the
cell phase ratio. Our experiment using live-imaging of
FUCCI cell-cycle progression following treatments with
carrageenan provided a clearer understanding regarding
this uncertainty. Time lapse imaging of individual FUCCI
cells treated by carrageenan was conducted to measure
precise cell cycle period. Cells treated with k-CO demon-
strated a longer time in both the G1 and G2/M phases of
the cell cycle compared with untreated cells. However, G2/
M phase time was double the time of the G1 phase in cells
treated with k-CO. This correlated with the previous result
of k-CO treatment stimulating cell-cycle arrest in G2 phase
because of a lengthening of the G2/M phase. Treatment
with λ-CO showed an even longer period in each cell cycle
checkpoints. Elongation of both the G1 and G2/M phase
which were almost at similar in length, in cells treated with
λ-CO explains the relatively equal ratio of G1 and G2/M
cells. Notably, cells treated with k-CO were largely able to
continue cell cycle progress to each phase and undergo cell
division, only the cell phase periods were longer than con-
trol. In contrast, cells treated with λ-CO mostly struggled
to continue the cell and hardly underwent division. This
finding supports the previous result of suppressed cell
growth following treatment with λ-CO. In conclusion both
carrageenans induce lengthening of the period in certain
phases of the cell cycle, generating a longer time to
complete the cycle compared with controls. These results,
suggest a different mechanism in both carrageenans affect-
ing tumor cell proliferation.
Conclusion
Our study findings suggest that carrageenan significantly
inhibits HeLa growth not only by arresting the cell cycle
in specific phases but also by causing a delay in cell cycle
progress. Furthermore, both λ-CO and k-CO have differ-
ent effects on the cell cycle in HeLa cells. k-CO was seen
to delay the cell cycle in G2/M phase while λ-CO stalled
the cell cycle in both G1 and G2/M phase, resulting in a
longer cell cycle compared with either k-CO treated and
untreated cells. Furthermore, λ-CO displayed suppres-
sion for the ability of the cell to divide, demonstrating a
strong anti-proliferative effect. In contrast, carrageenan
shows no significant effects towards HUVEC. However,
in vivo studies and trials on other human cancer and
normal cell lines are needed to confirm these results for
more advanced development of carrageenan as a poten-
tial anticancer agent.
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